Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: lipocalins - Pieris Pharmaceuticals

Drug Profile

Research programme: lipocalins - Pieris Pharmaceuticals

Alternative Names: Anticalin®; Anticalins®; CardioClean; DigiCal; OncoCal I; Pieries-110; PRS-010; PRS-030; PRS-055; PRS-056; PRS-070; PRS-090; PRS-110; PRS-130; PRS-190

Latest Information Update: 25 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris
  • Developer Allergan; Pieris; Pieris Pharmaceuticals; Zydus Cadila
  • Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lipocalins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 23 inhibitors; Interleukin-17 inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders; Eye disorders
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 25 Jan 2018 Lipocalin variants (Pieries-110) is still in preclinical development for Cancer in Germany (Zydus Cadila pipeline, January 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany
  • 01 Jul 2015 No development reported - Preclinical for Autoimmune disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top